Novo insulin beats Sanofi's Lantus in a comparative trial

05/5/2011 | Reuters

Novo Nordisk said degludec, an experimental long-acting insulin, proved superior to Sanofi-Aventis' best-seller Lantus in reducing hypoglycemia, particularly a nocturnal event, among patients with diabetes during a Phase IIIa trial. Novo Nordisk aims to market degludec and another formulation, degludec plus, during the first half of 2012.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Fremont, CA